Search Within

Solid Tumor Oncology Division

Formats
  1. Journal Article (10931)
  2. Meeting Abstract (9499)
  3. Review (556)
  4. Book Section (417)
  5. Editorial (336)
  6. Guidelines (158)
  7. Correspondence (118)
  8. Conference Paper (107)
  9. Research Letter (61)
  10. Miscellaneous (54)
  11. Book Whole (27)
Groups
  1. Department of Medicine (22241)
  2. GSK Faculty (5929)
  3. Genitourinary Oncology Service (5650)
  4. Survivorship Research (5226)
  5. Gastrointestinal Oncology Service (4692)
  6. Breast Medicine Service (4155)

More Groups

People
  1. Robert Motzer (1247)
  2. Howard Scher (1130)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (872)
  6. Leonard Saltz (792)

More People

Years
  1. 2025 (641)
  2. 2024 (1388)
  3. 2023 (1381)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1536)

More Years

Publications
  1. Journal of Clinical Oncology (5288)
  2. Annals of Oncology (1297)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (776)
  5. Journal of Thoracic Oncology (532)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5580)
  2. Elsevier Inc. (2662)
  3. American Association for Cancer Research (2327)
  4. Oxford University Press (1819)
  5. Nature Publishing Group (1043)
  6. Springer (981)

More Publishers

Results (22264)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Efficacy and clinicogenomic biomarkers of response to dual versus single agent checkpoint inhibitor therapy in untreated metastatic non-small cell lung cancer
    Meeting Abstract

    Boiarsky, D.; Hong, L.; Ricciuti, B.; Cooper, A. J.; Saad, M. B.; Elkrief, A.; Di Federico, A.; Aminu, M.; Rinsurongkawong, W.; Lewis, J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Enfortumab vedotin (EV) with pembrolizumab (P) versus chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Analysis of cisplatin (cis)-eligible population from EV-302/KEYNOTE-A39
    Meeting Abstract

    Bedke, J.; Van Der Heijden, M. S.; Powles, T.; Valderrama, B. P.; Kikuchi, E.; Iyer, G.; Vulsteke, C.; Swami, U.; Castellano, D.; Sarwar, N.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • irst-line inavolisib/placebo + palbociclib + fulvestrant (Inavo/Pbo+Palbo+Fulv) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer who relapsed during/within 12 months (mo) of adjuvant endocrine therapy completion: INAVO120 Phase III randomized trial additional analyses
    Meeting Abstract

    Juric, D.; Kalinsky, K.; Turner, N. C.; Jhaveri, K. L.; Schmid, P.; Loi, S.; Saura, C.; Im, S. A.; Sunpaweravong, P.; Li, H.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Updated overall survival analysis with 29-month follow-up of NAPOLI 3
    Meeting Abstract

    Hussein, M. A.; Khan, G.; Chandana, S. R.; Cid, R. A. P.; Kiss, I.; Gallego, J.; Macarulla, T.; De la Fouchardiere, C.; Goetze, T.; Dean, A. P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer (BC): Patient-reported outcomes (PROs) from the TROPION-Breast01 study
    Meeting Abstract

    Pernas, S.; Im, S. A.; Hattori, M.; Xu, B.; Wang, S.; Lu, Y. S.; Borges, G.; Tsurutani, J.; Jhaveri, K. L.; Zhang, Q. Y.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Enfortumab vedotin (EV) with pembrolizumab (P) versus chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Analysis of the cisplatin (cis)-ineligible population from EV-302/KEYNOTE-A39
    Meeting Abstract

    Van Der Heijden, M. S.; Gupta, S.; Bedke, J.; Valderrama, B. P.; Kikuchi, E.; Iyer, G.; Loriot, Y.; Dawson, N. A.; Hoffman-Censits, J. H.; Mar, N.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQoL) outcomes from the randomized, double-blind phase 3 KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC)
    Meeting Abstract

    Garassino, M. C.; Wakelee, H. A.; Spicer, J.; Liberman, M.; Kato, T.; Tsuboi, M.; Lee, S. H.; Chen, K. N.; Dooms, C. A.; Majem, M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Long-term efficacy and safety of larotrectinib (laro) in patients (pts) with TRK fusion thyroid carcinoma (TC)
    Meeting Abstract

    Cabanillas, M. E.; Lin, J. J.; Brose, M. S.; McDermott, R. S.; Almubarak, M.; Bauman, J. R.; Casanova, M.; Kummar, S.; Lee, S. H.; Leyvraz, S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients with muscle invasive bladder cancer (MIBC)-2-year event-free survival and safety data for Cohort H
    Meeting Abstract

    O'Donnell, P. H.; Hoimes, C. J.; Rosenberg, J. E.; Petrylak, D. P.; Mar, N.; Barata, P. C.; Srinivas, S.; Gourdin, T. S.; Henry, E.; Bilen, M. A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Efficacy and safety of erdafitinib in patients with advanced or metastatic cholangiocarcinoma and FGFR alterations: Pooled analysis of RAGNAR and LUC2001 studies
    Meeting Abstract

    Pant, S.; Park, J. O.; Su, W. C.; Schuler, M. H.; Loriot, Y.; Iyer, G.; Doi, T.; Qin, S.; Tabernero, J.; Prenen, H.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save